## Core Concept
The question revolves around the management of Parkinson's disease, specifically the interaction between levodopa and another drug that leads to a decrease in therapeutic effect. Levodopa is a precursor to dopamine, used to increase dopamine levels in Parkinson's disease patients. Carbidopa inhibits aromatic L-amino acid decarboxylase (AADC), which converts levodopa to dopamine outside the brain, thereby increasing the availability of levodopa to the brain.

## Why the Correct Answer is Right
The correct answer, **Pyridoxine (Vitamin B6)**, is known to accelerate the peripheral decarboxylation of levodopa to dopamine, thereby reducing its availability to the brain. When levodopa is given alone, pyridoxine can decrease its therapeutic effects by enhancing its peripheral conversion. However, when levodopa is combined with carbidopa, the carbidopa inhibits this peripheral conversion, making the effect of pyridoxine negligible.

## Why Each Wrong Option is Incorrect
- **Option A:** is not directly related to the interaction described.
- **Option B:** does not have a well-known interaction with levodopa that would decrease its effectiveness in this context.
- **Option D:** does not directly interfere with levodopa's mechanism or its conversion.

## Clinical Pearl / High-Yield Fact
A key point to remember is that when using levodopa for Parkinson's disease, combining it with carbidopa (as in levodopa-carbidopa) is crucial because carbidopa inhibits the peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain and thus enhancing its therapeutic effect while reducing side effects.

## Correct Answer: C. Pyridoxine.